Record Display for the EPA National Library Catalog

RECORD NUMBER: 14 OF 38

Main Title Inhalation Toxicology of Fog Oil Obscurant.
Author Grose, E. C. ; Selgrade, M. J. ; Davies, D. W. ; Stead, A. J. ;
CORP Author Environmental Protection Agency, Research Triangle Park, NC. Inhalation Toxicology Div.
Year Published 1986
Report Number 3E762777A878; CA;
Stock Number AD-A176 106/3
Additional Subjects Inhalation ; Smoke ; Toxicology ; Air ; Alveoli ; Clinical medicine ; Females ; Fog ; Lung ; Lung function tests ; Mineral oils ; Mortality rates ; Obscuration ; Oils ; Phagocytes ; Pneumonia ; Pulmonary function ; Rats ; Reticuloendothelial system ; Weight ; Exposure(Physiology) ; Toxicity ; Lethal dosage ; Polymorphonuclear leukocytes ; Paralysis ; Fog oils ; Concentration(Composition)
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  AD-A176 106/3 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 122p
Abstract
Sixty-day-old, male and female rats were exposed by inhalation to fog oil smoke. Mortality, LC50, subacute and subchronic studies were performed. Mortality studies showed fog oil smoke to be 100% lethal at 11.0 mg/L, 95% lethal at 5.0 mg/L, 20% lethal at 1.0 mg/L and 0% lethal at 0.1 mg/L after a 6-hour exposure. The observed LC50 of fog oil smoke after a 3.5-hr exposure was 5.2 mg/L. In the subacute and subchronic studies, rats were exposed to air, 0.2-, 0.5-, or 1.5-mg/L fog oil smoke for 3.5 hr/day, 4 days/wk for either 4 of 13 wk. Both pulmonary and systemic effects were investigated one day after the exposure ceased. For one 13-wk exposure group, animals were also examined 4 wk after the exposure. Following the srbacute 4-exposure to 1.5 mg/L, a multifocal pneumonitis was observed. Lung lavage had an elevated number of polymorphonuclear leukoctes (PMNs), alveolar macrophages and lung weights was observed after exposure to 0.5 mg/L. Pulmonary function tests revealed an increase in end expiratory volume (EEV) after 1.5mg/L. Systemic effects after the subacute exposure were minimal. A decrease in zoxazolamine-induced paralysis time was observed following both 0.5 and 1.5 mg/L; however, no effect on pentobarbital-induced sleeping time was observed. Behavioral studies were negative, as were clinical chemistries and immune function tests.